source
- Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecastsDeals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.BioSpace · 1mo ago↗ source
- Novartis faces another setback while Novo drops Nordisk partnershipThe latest edition of Endpoints Weekly notes that Novartis experienced another failure, though the newsletter does not provide details about the product or trial. It also reports that Novo Nordisk…
- Ultragenyx receives FDA approval for Fayuvi, first therapy for Sanfilippo syndrome type A, priced at $3.95 M